Keyword: Claire McCaskill
Advocacy groups and pharma companies often work hand in hand, but this year saw some of the shine wear off.
The U.S. Senate has released a report on Insys that provides an insider’s view of a company leaning on physicians to help drive sales.
Allowing direct Medicare drug price bargaining could save the Part D program $2.8 billion a year on the 20 most prescribed drug brands.
An influential senator said Teva is blocking her efforts to learn more about the company's opioid antidiversion programs.
In another pass at nixing pharma's ability to write off advertising expenses, Sen. McCaskill has introduced a new bill aimed at the DTC tax deduction.
Hundreds of cities and counties have sued to hold opioid makers accountable for the addiction epidemic. Now the feds are getting involved.
Sen. Sanders said it's time for Congress to force CEOs to testify on the opioid crisis as lawyers negotiate a potential settlement.
Current legislation doesn't include axing pharma's advertising deduction, but paying for other tax breaks may put it on the chopping block.
Five more lawmakers are piling on Allergan for the company's controversial tribal licensing deal.
Confronted with an investigation into its Vivitrol marketing, Alkermes contends it’s just trying to help the U.S. get control of the opioid crisis.